MGTX Live signals | Maximize Profits with Getagraph.com

SELL 99663 min ago

@ $6.39

Issued: 14 Feb 2024 @ 09:30

Return: -21.99%

Previous signal: Feb 13 - 09:30

Previous signal: Buy

Return: -2.44 %

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 15:30):

Stats
Today's Volume	121 223
Average Volume	147 945
Market Cap	317.03M
EPS	$0 ( 2024-03-12 )
Next earnings date	( $-0.320 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.35
ATR14	$0.00900 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-05	Forbes Alexandria	Sell	1 000	Ordinary Shares
2024-03-12	Forbes Alexandria	Sell	2 000	Ordinary Shares
2024-02-29	Giroux Richard	Sell	13 500	Ordinary Shares
2024-01-07	Zeldin Robert K	Sell	13 773	Ordinary Shares
2024-01-14	Giroux Richard	Buy	25 000	Ordinary Shares

INSIDER POWER
-5.88
Last 100 transactions
Buy: 8 402 826 \| Sell: 8 030 781

Volume Correlation

Long: 0.09 (neutral)

Short: -0.04 (neutral)

Signal:(37.119) Neutral

MeiraGTx Holdings PLC Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

MeiraGTx Holdings PLC Correlation - Currency/Commodity

0.40
( neutral )

0.47
( neutral )

0.00
( neutral )

0.43
( neutral )

0.00
( neutral )

-0.51
( weak negative )

MeiraGTx Holdings PLC Financials

Annual	2023
Revenue:	$14.02M
Gross Profit:	$287 000 (2.05 %)
EPS:	$-1.490

Q4	2023
Revenue:	$2.04M
Gross Profit:	$-1.87M (-91.76 %)
EPS:	$0.320

Q3	2023
Revenue:	$5.10M
Gross Profit:	$1.62M (31.82 %)
EPS:	$-0.740

Q2	2023
Revenue:	$3.54M
Gross Profit:	$293 000 (8.28 %)
EPS:	$-0.530

Financial Reports:

No articles found.

MeiraGTx Holdings PLC

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.